GlassScriptPhysician profile
Verghese Mathew
NPI 1093795627
$7,825.80
in general payments reported to CMS, 2019-2025
32 companies · $1,006 in 2025
The $1,006 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $521 · 2021: $364 · 2022: $2,873 · 2023: $1,130 · 2024: $1,663 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,799.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Change Healthcare Technologies, LLC | $2,600.00 | 2022 | |
| Edwards Lifesciences Corporation | $1,858.58 | 2019-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $591.63 | 2022-2025 | |
| Integer Holdings Corporation | $400.00 | 2020 | |
| Boston Scientific Corporation | $224.79 | 2019-2021 | |
| Cleerly, INC. | $219.94 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.24 | 2023-2025 | Lifevest |
| Inari Medical, INC. | $176.01 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $172.45 | 2021-2025 | Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $140.48 | 2022-2024 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $136.93 | 2024 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $132.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.88 | 2023-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $111.45 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $92.73 | 2022-2024 | Verquvo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $79.91 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| E.R. Squibb & Sons, L.L.C. | $65.07 | 2024-2025 | Eliquis, Camzyos |
| Amgen INC. | $63.33 | 2024-2025 | Repatha, Repatha |
| Imperative Care, INC | $52.70 | 2024 | Symphony Catheter |
| Janssen Pharmaceuticals, INC | $50.28 | 2022 | |
| Shockwave Medical, INC | $39.44 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $36.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.89 | 2022 | |
| Stryker Corporation | $31.50 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $29.66 | 2024 | Wegovy |
| Altathera Pharmaceuticals LLC | $28.03 | 2025 | Sotalol Hydrochloride |
| Scpharmaceuticals INC. | $23.25 | 2025 | |
| Abiomed | $22.66 | 2025 | |
| Cordis US Corp. | $19.02 | 2025 | Mynx Control Venous |
| Teleflex LLC | $18.48 | 2025 | Manta |
| Elutia, INC. | $17.40 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Verghese Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.